"Torsade de pointes" during amiodarone infusion in a cirrhotic woman with a prolonged QT interval

Digestive and Liver Disease

Volumn 41, Issue 7, 2009, Pages 535-538

  Di Micoli, A ^a   Zambruni, A ^a   Bracci, E ^a   Benazzi, B ^a   Zappoli, P ^a   Berzigotti, A ^a   Zoli, M ^a   Bernardi, M ^a   Trevisani, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Amiodarone; Cirrhosis; QT interval; Torsade de pointes

Indexed keywords

ALBUMIN; AMIODARONE; FUROSEMIDE; LACTULOSE; METOPROLOL; SPIRONOLACTONE; VITAMIN;

AGED; ARTICLE; CARDIOVERSION; CASE REPORT; CLINICAL PRACTICE; DECOMPENSATED LIVER CIRRHOSIS; DRUG INFUSION; FEMALE; HEART ATRIUM FIBRILLATION; HEART REPOLARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIVER CIRRHOSIS; PRIORITY JOURNAL; QT PROLONGATION; SINUS RHYTHM; TORSADE DES POINTES;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; TACHYCARDIA, SUPRAVENTRICULAR; TORSADES DE POINTES;

EID: 67349125743     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.11.017     Document Type: Article

References (26)

1. Dekker J.M., Crow R.S., Hannan P.J., Schouten E.G., and Folsom A.R. ARIC study: heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study. J Am Coll Cardiol 43 (2004) 565-571
2. Zambruni A., Trevisani F., Caraceni P., and Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatols 44 (2006) 994-1002
3. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 350 (2004) 1013-1022
4. Faigel D.O., Metz D.C., and Kochman M.L. Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance. Am J Gastroenterol 90 (1995) 822-824
5. Nakasone H., Sugama R., Sakugawa H., Matayoshi R., Miyagi T., Maeshiro T., et al. Alcoholic liver cirrhosis complicated with torsade de pointes during plasma exchange and hemodiafiltration. J Gastroenterol 36 (2001) 564-568
6. Lustik S.J., Eichelberger J.P., Chibber A.K., and Bronsther O. Torsade de pointes during orthotopic liver transplantation. Anesth Analg 87 (1998) 300-303
7. Kamisako T., Adachi Y., Nakagawa H., and Yamamoto T. Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. Intern Med 34 (1995) 92-95
8. Hohnloser S.H., Klingenheben T., and Singh B.N. Amiodarone-associated proarrhythmic effects. A review with special reference to Torsade de pointes tachycardia. Ann Intern Med 121 (1994) 529-535
9. Moro C., Romero J., and Corres Peiretti M.A. Amiodarone and hypokalemia. A dangerous combination. Int J Cardiol 13 (1986) 365-368
10. Middlekauff H.R., Stevenson W.G., Saxon L.A., and Stevenson L.W. Amiodarone and torsades de pointes in patients with advanced heart failure. Am J Cardiol 76 (1995) 499-502
11. Yamada S., Kuga K., and Yamaguchi I. Torsade de pointes induced by intravenous and long-term oral amiodarone therapy in a patient with dilated cardiomyopathy. Jpn Circ J 65 (2001) 236-238
12. Zambruni A., Di Micoli A., Lubisco A., Domenicali M., Trevisani F., and Bernardi M. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol 18 (2007) 77-82
13. Topilski I., Rogowski O., Rosso R., Justo D., Copperman Y., Glikson M., et al. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol 49 (2007) 320-328
14. Priori S.G., Napolitano C., and Schwartz P.J. Low penetrance in the long-QT syndrome: clinical impact. Circulation 99 (1999) 529-533
15. Bernardi M., Calandra S., Colantoni A., Trevisani F., Raimondo M.L., Sica G., et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27 (1998) 28-34
16. Waldhauser K.M., Török M., Ha H.R., Thomet U., Konrad D., Brecht K., et al. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodaronederivatives. J Pharmacol Exp Ther 319 (2006) 1413-1423
17. Schrickel J.W., Schwab J.O., Yang A., Bitzen A., Luderitz B., and Lewater T. "Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis. Pacing Clin Electrophysiol 29 (2006) 363-366
18. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 356 (2007) 935-941
19. Singh B.N., Singh S.N., Reda D.J., Tang X.C., Lopez B., Harris C.L., et al. Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 (2005) 1861-1872
20. Kochiadakis G.E., Igoumenidis N.E., Solomou M.C., Kaleboubas M.D., Chlouverakis G.I., and Vardas P.E. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol 83 (1999) 58-61
21. Malik M. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol 25 (2002) 209-216
22. Henriksen J.H., Bendtsen F., Hansen E.F., and Moeller S. Acute non-selective β-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval in patients with cirrhosis. J Hepatol 40 (2004) 239-246
23. Lee S.S., Marty J., Mantz J., Samain E., Braillon A., and Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology 12 (1990) 481-485
24. Ma Z., Meddings J.B., and Lee S.S. Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am J Physiol 267 (1994) G87-G93
25. Ma Z., Miyamoto A., and Lee S.S. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 110 (1996) 1191-1198
26. Zavecz J.H., Battarbee H.D., and O'Donnell J.M. Cardiac beta-adrenoceptor-effector coupling in portal vein-stenosed rats. Am J Physiol 268 (1995) G410-G415